Literature DB >> 19487675

Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal carcinoma.

Zachary S Morris1, Andrea I McClatchey.   

Abstract

The epidermal growth factor receptor (EGFR) has frequently been implicated in hyperproliferative diseases of renal tubule epithelia. We have shown that the NF2 tumor suppressor Merlin inhibits EGFR internalization and signaling in a cell contact-dependent manner. Interestingly, despite the paucity of recurring mutations in human renal cell carcinoma (RCC), homozygous mutation of the NF2 gene is found in approximately 2% of RCC patient samples in the Sanger COSMIC database. To examine the roles of Merlin and EGFR in kidney tumorigenesis, we generated mice with a targeted deletion of Nf2 in the proximal convoluted epithelium using a Villin-Cre transgene. All of these mice developed intratubular neoplasia by 3 months, which progressed to invasive carcinoma by 6-10 months. Kidneys from these mice demonstrated marked hyperproliferation and a concomitant increase in label-retaining putative progenitor cells. Early lumen-filling lesions in this model exhibited hyperactivation of EGFR signaling, altered solubility of adherens junctions components, and loss of epithelial polarity. Renal cortical epithelial cells derived from either early or late lesions were dependent on EGF for in vitro proliferation and were arrested by pharmacologic inhibition of EGFR or re-expression of Nf2. These cells formed malignant tumors upon s.c. injection into immunocompromised mice before in vitro passage. Treatment of Vil-Cre;Nf2(lox/lox) mice with the EGFR inhibitor erlotinib halted the proliferation of tumor cells. These studies give added credence to the role of EGFR signaling and perhaps Nf2 deficiency in RCC and describe a rare and valuable mouse model for exploring the molecular basis of this disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19487675      PMCID: PMC2700996          DOI: 10.1073/pnas.0902031106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  57 in total

Review 1.  Renal-cell carcinoma.

Authors:  Herbert T Cohen; Francis J McGovern
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

Review 2.  Renal-cell carcinoma.

Authors:  R J Motzer; N H Bander; D M Nanus
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

Review 3.  Epithelial cell growth and differentiation. IV. Controlled spatiotemporal expression of transgenes: new tools to study normal and pathological states.

Authors:  S Robine; F Jaisser; D Louvard
Journal:  Am J Physiol       Date:  1997-10

4.  Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma.

Authors:  H Moch; G Sauter; N Buchholz; T C Gasser; L Bubendorf; F M Waldman; M J Mihatsch
Journal:  Hum Pathol       Date:  1997-11       Impact factor: 3.466

5.  Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2.

Authors:  M Giovannini; E Robanus-Maandag; M van der Valk; M Niwa-Kawakita; V Abramowski; L Goutebroze; J M Woodruff; A Berns; G Thomas
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

6.  Adult stem cell-like tubular cells reside in the corticomedullary junction of the kidney.

Authors:  Kyungeun Kim; Kyoung Mee Lee; Duck Jong Han; Eunsil Yu; Yong Mee Cho
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

7.  Epidermal growth factor-stimulated tyrosine phosphorylation of caveolin-1. Enhanced caveolin-1 tyrosine phosphorylation following aberrant epidermal growth factor receptor status.

Authors:  Y N Kim; G J Wiepz; A G Guadarrama; P J Bertics
Journal:  J Biol Chem       Date:  2000-03-17       Impact factor: 5.157

Review 8.  Origin of renal cell carcinomas.

Authors:  Manuel Valladares Ayerbes; Guadalupe Aparicio Gallego; Silvia Díaz Prado; Paula Jiménez Fonseca; Rosario García Campelo; Luis Miguel Antón Aparicio
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.405

9.  Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.

Authors:  Eric K Rowinsky; Garry H Schwartz; Jared A Gollob; John A Thompson; Nicholas J Vogelzang; Robert Figlin; Ronald Bukowski; Naomi Haas; Pamela Lockbaum; Yu-Ping Li; Rosalin Arends; Kenneth A Foon; Gisela Schwab; Janice Dutcher
Journal:  J Clin Oncol       Date:  2004-06-21       Impact factor: 44.544

10.  Characterization of primary rabbit kidney cultures that express proximal tubule functions in a hormonally defined medium.

Authors:  S D Chung; N Alavi; D Livingston; S Hiller; M Taub
Journal:  J Cell Biol       Date:  1982-10       Impact factor: 10.539

View more
  27 in total

1.  Merlin/NF2 Suppresses Pancreatic Tumor Growth and Metastasis by Attenuating the FOXM1-Mediated Wnt/β-Catenin Signaling.

Authors:  Ming Quan; Jiujie Cui; Tian Xia; Zhiliang Jia; Dacheng Xie; Daoyan Wei; Suyun Huang; Qian Huang; Shaojiang Zheng; Keping Xie
Journal:  Cancer Res       Date:  2015-10-19       Impact factor: 12.701

2.  Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver.

Authors:  Samira Benhamouche; Marcello Curto; Ichiko Saotome; Andrew B Gladden; Ching-Hui Liu; Marco Giovannini; Andrea I McClatchey
Journal:  Genes Dev       Date:  2010-07-30       Impact factor: 11.361

3.  Merlin/ERM proteins establish cortical asymmetry and centrosome position.

Authors:  Alan M Hebert; Brian DuBoff; Jessica B Casaletto; Andrew B Gladden; Andrea I McClatchey
Journal:  Genes Dev       Date:  2012-12-15       Impact factor: 11.361

4.  p120-Catenin is an obligate haploinsufficient tumor suppressor in intestinal neoplasia.

Authors:  Sarah P Short; Jumpei Kondo; Whitney G Smalley-Freed; Haruna Takeda; Michael R Dohn; Anne E Powell; Robert H Carnahan; Mary K Washington; Manish Tripathi; D Michael Payne; Nancy A Jenkins; Neal G Copeland; Robert J Coffey; Albert B Reynolds
Journal:  J Clin Invest       Date:  2017-11-13       Impact factor: 14.808

Review 5.  Spatial regulation of receptor tyrosine kinases in development and cancer.

Authors:  Jessica B Casaletto; Andrea I McClatchey
Journal:  Nat Rev Cancer       Date:  2012-05-24       Impact factor: 60.716

6.  A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions.

Authors:  Chunling Yi; Scott Troutman; Daniela Fera; Anat Stemmer-Rachamimov; Jacqueline L Avila; Neepa Christian; Nathalie Luna Persson; Akihiko Shimono; David W Speicher; Ronen Marmorstein; Lars Holmgren; Joseph L Kissil
Journal:  Cancer Cell       Date:  2011-04-12       Impact factor: 31.743

7.  Thyroid-specific knockout of the tumor suppressor mitogen-inducible gene 6 activates epidermal growth factor receptor signaling pathways and suppresses nuclear factor-κB activity.

Authors:  Chi-Iou Lin; Justine A Barletta; Matthew A Nehs; Zachary S Morris; David B Donner; Edward E Whang; Jae-wook Jeong; Shioko Kimura; Francis D Moore; Daniel T Ruan
Journal:  Surgery       Date:  2011-12       Impact factor: 3.982

8.  Loss of NF2/Merlin expression in advanced sporadic colorectal cancer.

Authors:  Tamara Cačev; Gorana Aralica; Božo Lončar; Sanja Kapitanović
Journal:  Cell Oncol (Dordr)       Date:  2013-12-10       Impact factor: 6.730

9.  Tumor suppressor NF2/Merlin is a microtubule stabilizer.

Authors:  Zlatko Smole; Claudio R Thoma; Kathryn T Applegate; Maria Duda; Katrin L Gutbrodt; Gaudenz Danuser; Wilhelm Krek
Journal:  Cancer Res       Date:  2013-11-26       Impact factor: 12.701

Review 10.  Hippo signaling in the kidney: the good and the bad.

Authors:  Jenny S Wong; Kristin Meliambro; Justina Ray; Kirk N Campbell
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.